Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

RCT (n=388) found addition of daratumumab, a human CD38-targeting antibody, to bortezomib, cyclophosphamide, and dexamethasone was linked to higher frequencies of haematologic complete response (53.3% vs. 18.1%; relative risk ratio, 2.9; 95% CI, 2.1 to 4.1; p<0.001).

Source:

New England Journal of Medicine